{
  "id": "5e2902688b3851296d000005",
  "type": "factoid",
  "question": "Which receptor is inhibited by Teprotumumab?",
  "ideal_answer": "Teprotumumab is a monoclonal inhibitory antibody targeting IGF-1 receptor.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28427155",
    "http://www.ncbi.nlm.nih.gov/pubmed/26287404",
    "http://www.ncbi.nlm.nih.gov/pubmed/24878056",
    "http://www.ncbi.nlm.nih.gov/pubmed/26087256",
    "http://www.ncbi.nlm.nih.gov/pubmed/29273685",
    "http://www.ncbi.nlm.nih.gov/pubmed/30575804",
    "http://www.ncbi.nlm.nih.gov/pubmed/28467880",
    "http://www.ncbi.nlm.nih.gov/pubmed/29744034",
    "http://www.ncbi.nlm.nih.gov/pubmed/30215690",
    "http://www.ncbi.nlm.nih.gov/pubmed/27346786",
    "http://www.ncbi.nlm.nih.gov/pubmed/29847668",
    "http://www.ncbi.nlm.nih.gov/pubmed/25105999"
  ],
  "snippets": [
    {
      "text": "A recently completed therapeutic trial of teprotumumab, a human IGF1R inhibiting antibody, in patients with moderate to severe, active TAO, indicates the potential effectiveness and safety of the drug. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29273685",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results from a very recently published clinical trial assessing the safety and efficacy of teprotumumab, an inhibitory human anti-IGF-IR monoclonal antibody, in active, moderate to severe TAO are extremely encouraging.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29744034",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The induction in fibrocytes is a consequence of increased TNF-\u03b1 gene promoter activity and is independent of ongoing protein synthesis. It could be attenuated by dexamethasone and the IGF-1 receptor inhibiting antibody, teprotumumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29847668",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These observations served as the rationale for implementing a recently completed therapeutic trial of teprotumumab, a monoclonal inhibitory antibody targeting IGF-IR in TAO. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30215690",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results of randomised controlled trials investigating the efficacy of the IGF-1 receptor antibody teprotumumab and the interleukin-6 receptor antibody tocilizumab are expected shortly.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27346786",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28427155",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "METHODS: We conducted a multicenter, double-masked, randomized, placebo-controlled trial to determine the efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patients with active, moderate-to-severe ophthalmopathy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467880",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TSH-Mediated TNF\u03b1 Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26087256",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Teprotumumab (TMB) is a human monoclonal IGF-1R blocking antibody currently in clinical trial for GO and inhibits TSHR-mediated actions in FCs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26087256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS Teprotumumab attenuates the actions of both IGF-1 and TSH in fibrocytes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24878056",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24878056",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "DESIGN Fibrocytes were treated without or with teprotumumab in combination with IGF-1 or TSH.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24878056",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30575804",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "TSH-Mediated TNF\u03b1 Production in Human Fibrocytes Is Inhibited by Teprotumumab , an IGF-1R Antagonist",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26087256",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Teprotumumab ( TMB ) is a human monoclonal IGF-1R blocking antibody currently in clinical trial for GO and inhibits TSHR-mediated actions in FCs",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26087256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teprotumumab (TMB) is a human monoclonal IGF-1R blocking antibody currently in clinical trial for GO and inhibits TSHR-mediated actions in FCs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26087256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teprotumumab, a monoclonal IGF-1R antagonist, has demonstrated previously in a 24 week, randomized, controlled trial to produce significant changes in composite outcomes of proptosis and clinical activity score as compared with placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30575804",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "METHODS\nWe conducted a multicenter, double-masked, randomized, placebo-controlled trial to determine the efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patients with active, moderate-to-severe ophthalmopathy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467880",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teprotumumab (RV 001, R1507) is a human monoclonal anti-IGF-1R blocking antibody currently undergoing a phase 2 clinical trial in patients with active TAO.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24878056",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The most promising results are observed with small thyroid stimulating hormone receptor molecules interacting with the receptor on thyrocytes and fibroblasts and with the anti-IGF-1 receptor antibody teprotumumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25105999",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The induction could be attenuated by dexamethasone and by IGF-I receptor-blocking antibodies, teprotumumab and 1H7.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26287404",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teprotumumab (RV 001, R1507) is a human monoclonal anti-IGF-1R blocking antibody currently undergoing a phase 2 clinical trial in patients with active TAO.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24878056",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The most promising results are observed with small thyroid stimulating hormone receptor molecules interacting with the receptor on thyrocytes and fibroblasts and with the anti-IGF-1 receptor antibody teprotumumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25105999",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teprotumumab, a monoclonal IGF-1R antagonist, has demonstrated previously in a 24 week, randomized, controlled trial to produce significant changes in composite outcomes of proptosis and clinical activity score as compared with placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30575804",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "IGF-1"
}